Key result
Guideline-based risk stratification identified ICD indications in 56% of Omani HCM patients per 2020 AHA/ACC criteria, but only 25% underwent ICD implantation, and 6 died from arrhythmic causes.
Why the study?
Data on hypertrophic cardiomyopathy from the Middle East remain limited, and the clinical phenotype, arrhythmic risk, and implementation of sudden cardiac death prevention strategies in Oman are not well characterized.
What are the clinical characteristics, arrhythmic outcomes, and ICD utilization rates according to contemporary risk-stratification strategies in patients with hypertrophic cardiomyopathy in Oman?
Cohort (n=110)
Yes
What are the clinical characteristics, arrhythmic outcomes, and ICD utilization rates according to contemporary risk-stratification strategies in patients with hypertrophic cardiomyopathy in Oman?
This multicenter Omani cohort reveals a young HCM patient population with substantial arrhythmic risk and a large implementation gap between guideline-recommended ICD eligibility (56%) and actual implantation (25%).
Answers are grounded in this paper and cite their sources.
Highlights ICD underutilization in Omani HCM despite guideline indications; extends risk-stratification data to this population but leaves clinical impact open.
Background Hypertrophic cardiomyopathy (HCM) is a common inherited cardiomyopathy, but data from the Middle East remain limited. The clinical phenotype, arrhythmic risk, and implementation of sudden cardiac death prevention strategies in Oman are not well characterized. Objectives To describe the clinical and imaging characteristics of HCM in Oman and evaluate arrhythmic outcomes and implantable cardioverter-defibrillator (ICD) utilization according to contemporary risk-stratification strategies. Methods This retrospective multicenter cohort included patients aged ≥16 years diagnosed with HCM at the two largest cardiology services in Oman between January 2016 and December 2023. Clinical, imaging, ICD, and genetic data were collected. ICD eligibility was assessed using 2020 AHA/ACC recommendations and the ESC HCM Risk-SCD calculator. Results Among 110 patients, mean age at diagnosis was 35 ± 17 years and 78% were male; 75% were sporadic cases. Presenting symptoms included palpitations (33%), dyspnea (31%), chest pain (24%), and syncope (12%). Atrial fibrillation occurred in 16%. Mean maximum LV wall thickness was 22 ± 6 mm, with septal HCM predominating (68%). Septal reduction therapy was performed in 7 patients. According to 2020 AHA/ACC recommendations, 62 patients (56%) had an ICD indication, but only 27 (25%) underwent implantation. Using an ESC HCM Risk-SCD threshold >6% at 5 years, 10 patients (9%) were high risk and 7 received an ICD. Seven patients had appropriate ICD therapies for ventricular tachycardia. Six patients died from arrhythmic causes; none had a prior ICD or cardiac MRI. Conclusions This Omani HCM cohort demonstrates a young patient population, substantial arrhythmic burden, and a marked gap between guideline-based ICD eligibility and implantation, highlighting the need for systematic risk stratification and structured HCM care pathways.
No takes yet. Share an insight, caveat, or question.
Habsi et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (n=110). Risk stratification and implantable cardioverter-defibrillator (ICD) utilization (2020 AHA/ACC recommendations and ESC HCM Risk-SCD calculator) was evaluated on ICD eligibility and implantation, appropriate ICD therapies, and arrhythmic death. Guideline-based risk stratification identified ICD indications in 56% of Omani HCM patients per 2020 AHA/ACC criteria, but only 25% underwent ICD implantation, and 6 died from arrhythmic causes.
Synapse has enriched 10 related papers. Consider them for comparative context: